The RA Workload Behind Every Breakthrough Device Interaction
DTx programs at the $1M–$8M range routinely carry significant RA advisory costs, particularly when navigating Breakthrough Device designation and the Pre-Submission process. FDA Q-submissions require cover letters that frame the clinical question precisely, clinical evidence summaries that follow FDA's own DTx-specific guidance, and response tracking that keeps the program's FDA engagement calendar on schedule. When CMO teams manage this through Confluence documentation and email-based coordination with RA advisors, the workload is high and the advisory costs reflect it — for work that is structurally rule-following.
How the Agent Manages the Q-Sub and Evidence Summary Pipeline
An AI Labor Company agent mines FDA Q-submission and Breakthrough Device designation request workflows from the CMO team's regulatory-affairs Confluence and FDA meeting-minute logs. It auto-drafts Pre-Sub Q-sub cover letters, compiles clinical evidence summaries per current FDA DTx guidance, and maintains a live tracker of FDA response timelines and expected meeting dates. The CMO approves all FDA-facing communications before submission — no document goes out without sign-off. The agent handles the structural assembly and guidance alignment; the CMO owns the scientific and regulatory judgment calls. Deployment runs approximately twelve weeks.
RA Cost Recovery and Faster FDA Engagement Cycles
Reducing RA advisory consulting spend by an illustrative 35% per DTx program is a direct cost story, but the more consequential benefit is the feedback loop between FDA interactions. When Pre-Sub documents are drafted and reviewed faster, the program can compress the time between Q-submission submission and FDA meeting scheduling — which accelerates the clinical evidence generation timeline that precedes De Novo or 510(k) clearance. An agent handling 40–60% of the document drafting and tracking workload also means the CMO and RA team are spending their time on FDA dialogue strategy rather than document assembly, which is where their expertise creates the most program value.
Does the agent stay current with FDA DTx guidance updates?
The agent is configured against the FDA DTx guidance documents active at deployment. When guidance is updated, the agent's evidence summary templates are reviewed and updated as part of the ongoing service relationship — this is not a set-and-forget configuration.
Can the agent draft responses to FDA information requests or only outgoing submissions?
The current workflow covers outgoing Pre-Sub Q-submissions and clinical evidence summaries. FDA information request responses involve additional review complexity and are handled as a supervised drafting workflow with CMO approval at each section.